Find, compare & contact
Dihydroxyaluminum sodium carbonate
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Dihydroxyaluminum sodium carbonate API 16482-55-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Dihydroxyaluminum sodium carbonate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Dihydroxyaluminum sodium carbonate
- Synonyms:
- Aluminium-natrium-carbonat-dihydroxid , Aluminum sodium dihydroxide monocarbonate , Dihydroxo-aluminium-natrium-carbonat , Dihydroxyaluminum sodium carbonate
- Cas Number:
- 16482-55-6
- DrugBank number:
- DB15825
- Unique Ingredient Identifier:
- 84H8Z9550J
General Description:
Dihydroxyaluminum sodium carbonate is a chemical compound identified by the CAS number 16482-55-6. It is known for its distinct pharmacological properties and applications.
Categories:
Dihydroxyaluminum sodium carbonate is categorized under the following therapeutic classes: Alkalies, Aluminium Compounds, Anions, Electrolytes, Hydroxides, Ions, Metal cations, Metal divalent cations. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Dihydroxyaluminum sodium carbonate is a type of Alkalinizing agents
Alkalinizing agents, a pharmaceutical API category, refers to a group of substances used to increase the pH (alkalinity) of a solution or body fluid. These agents play a crucial role in various medical applications, such as the treatment of acidosis, kidney disorders, and certain drug overdoses.
One commonly used alkalinizing agent is sodium bicarbonate, which is highly effective in raising the pH of blood and urine. It works by neutralizing excess acid and restoring the acid-base balance in the body. Sodium bicarbonate is often administered intravenously in emergency situations to rapidly correct severe acidosis.
Another alkalinizing agent, acetazolamide, is frequently employed in the treatment of glaucoma and certain types of epilepsy. By inhibiting carbonic anhydrase, acetazolamide reduces the production of bicarbonate ions, leading to a systemic decrease in pH. This mechanism is particularly useful in lowering the intraocular pressure associated with glaucoma.
Alkalinizing agents are also utilized in the management of certain drug toxicities. For instance, methotrexate, a chemotherapy medication, can cause severe toxicity if its elimination is hindered. Alkalinizing the urine with agents like sodium bicarbonate enhances methotrexate solubility, preventing the formation of toxic crystals in the kidneys.
In conclusion, alkalinizing agents are indispensable pharmaceutical APIs that help correct acid-base imbalances, treat specific medical conditions, and mitigate drug toxicities. Their diverse applications make them valuable tools in modern medicine.
